View Cart  

FDA Considers Guidance on Ad Claims Comparing Competing Drugs

A sharp increase in exaggerated or misleading comparative claims in drug advertisements has the FDA analyzing the issue and considering guidance to help stop the violations.

To View This Article:


Subscribe To The Executive Briefing Series

Buy This Article Now

Add this article to your cart for $40.00